Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
FY2016 Earnings Roundup - 1: Japan’s Growth Potential Falters Despite 2.2% CAGR from FY2010
By Reiji Anasako Japanese drug makers floundered both on the revenue and operating profit fronts in FY2016, which ended in March for most of these companies, as they faced drug price cuts at home and the stronger yen abroad. With…
To read the full story
Related Article
- FY2016 Earnings Roundup - 5: Drug Makers Anticipate Nearly Flat Growth in FY2017; Mid-Term Outlook Unclear
June 2, 2017
- FY2016 Earnings Roundup - 4: Average Productivity per Sales Rep Up Only 14 Million Yen in 6 Years
June 1, 2017
- FY2016 Earnings Roundup - 3: Price Battle Batters Generic Makers, 3 Majors’ Profit Rate in Single-Digits
May 31, 2017
- FY2016 Earnings Roundup - 2: Entyvio Robust, Xtandi Treads Water as Global Brands Underpin Revenue
May 30, 2017
- FY2016 Sales Dip for 27 Japan Makers, Second-Tier/Mid-Sized Firms Fare Well: Jiho Tally
May 24, 2017
BUSINESS
- Leqembi FY2025 Global Sales Reach 88 Billion Yen: Eisai
May 1, 2026
- Rohto Files CMV Corneal Endotheliitis Drug in Japan
May 1, 2026
- Mochida Files in Japan for PAH Drug Tyvaso DPI
May 1, 2026
- Tanabe Clinches EU Approval for Parkinson’s Drug Onerji
May 1, 2026
- 3D “Deeply Disappointed” by Toho Plan to Seek Defense Trigger Approval
May 1, 2026
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…